ALVR Live signals | Maximize Profits with Getagraph.com

BUY 93545 min ago

@ $0.677

Issued: 14 Feb 2024 @ 15:54

Return: 10.76%

Previous signal: Feb 13 - 13:31

Previous signal: Sell

Return: 0.83 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	290 769
Average Volume	865 282
Market Cap	85.57M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $-0.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00200 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Miller Edward	Sell	368	Common Stock
2024-04-02	Brainard Diana	Sell	1 533	Common Stock
2024-04-02	Hagen Brett R	Sell	281	Common Stock
2024-04-02	Sinha Vikas	Sell	885	Common Stock
2024-02-20	Brainard Diana	Sell	3 097	Common Stock

INSIDER POWER
83.33
Last 98 transactions
Buy: 5 809 216 \| Sell: 487 374

Volume Correlation

Long: 0.09 (neutral)

Short: -0.82 (strong negative)

Signal:(45.394) Neutral

AlloVir, Inc. Correlation

10 Most Positive Correlations
BCLI	0.953
CVAC	0.952
CRNC	0.951
RSLS	0.949
PYPD	0.948
LYT	0.947
IKT	0.944
TNYA	0.944
RANI	0.943
SONN	0.942

10 Most Negative Correlations
EBSB	-0.952
HERA	-0.95
ISEE	-0.949
FXCO	-0.946
MTRX	-0.944
GXII	-0.943
FTPA	-0.943
NOVV	-0.943
TBSA	-0.942
HERAU	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AlloVir, Inc. Correlation - Currency/Commodity

0.21
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.16
( neutral )

AlloVir, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-398 000 (0.00 %)
EPS:	$-1.830

Q4	2023
Revenue:	$0
Gross Profit:	$-141 000 (0.00 %)
EPS:	$-0.520

Q3	2023
Revenue:	$0
Gross Profit:	$-3.64M (0.00 %)
EPS:	$-0.390

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.480

Financial Reports:

No articles found.

AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.